Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Reaffirms $41M Offer for Exact

NEW YORK (GenomeWeb News) — Sequenom today said it plans to try to go ahead with its attempt to buy Exact Sciences for $1.50 a share, or around $41 million, in an all-stock transaction despite Exact's refusal on Monday to accept the offer, which Sequenom put forward at the end of last week.

Exact said its board agreed unanimously to decline the proposal, and said in a statement that it is "actively pursuing" an alternative that could better serve its shareholders.

Sequenom CEO Harry Stylii said in a statement today that his company was "disappointed" in Exact's refusal. He said the acquisition of Exact's colorectal cancer-screening technologies would allow Sequenom to hold "one of the most comprehensive noninvasive cancer diagnostic portfolios."

Stylii said his company is "concerned that Exact may enter into transactions which may not be in the best interest of its shareholders," and said his company will "immediately withdraw our offer" if Exact enters into any material outlicensing agreement.

Stylii explained that Sequenom is holding fast to its offer because it believes Exact "is essentially a shell with intellectual property assets, and [it] would be straightforward to assimilate the assets into our operations with minimal near-term cash outlay and execution risk to our current initiatives."

Exact also is "facing significant business challenges," Stylii added, explaining that his company's offer would enable Exact's shareholders to avoid possible delisting on the Nasdaq Capital Market, "uncertain prospects for future financing, the need for further restructuring, and significant execution risk."

The original purchase would have been a 69-percent premium on Exact Sciences stock price of $.89 a share on the day of the offer. This morning, Exact's stock was trading on the Nasdaq at $1.68 a share.

Filed under

The Scan

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.

Seagull Microbiome Altered by Microplastic Exposure

The overall diversity and the composition at gut microbiome sites appear to coincide with microplastic exposure and ingestion in two wild bird species, according to a new Nature Ecology and Evolution study.

Study Traces Bladder Cancer Risk Contributors in Organ Transplant Recipients

In eLife, genome and transcriptome sequencing reveal mutation signatures, recurrent somatic mutations, and risky virus sequences in bladder cancers occurring in transplant recipients.

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.